Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. Sacubitril is rapidly converted to LBQ657 (active metabolite) by carboxylesterases and the active metabolite is not further metabolized to a significant extent. Sacubitril inhibits OATP1B1 and LBQ657 is a substrate of OATP1B1/3, OAT1 and OAT3. Based on metabolism and clearance a clinically significant interaction with emtricitabine is unlikely. Tenofovir is eliminated via OAT1 and therefore could potentially compete with LBQ657 renal elimination (clinical relevance is unclear). Start with the lowest recommended dose of sacubitril and titrate dosage as tolerated by the patient.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking